At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 10 enrolled
Drug / intervention
TAK-123drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Center, Open-Label, Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of TAK-123 After Intravenous Infusion in Japanese Healthy Adult Male Subjects
In Brief
A Phase 1 clinical trial evaluating TAK-123 for Healthy Volunteers. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the PK, safety and tolerability of phenylacetate and benzoate after intravenous administration of TAK-123 in Japanese healthy adult male participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartNov 2019
Primary CompletionDec 2019
TodayJul 2026
First PostedNov 7, 2019
Enrollment StartNov 13, 2019
Primary CompletionDec 6, 2019
TodayJul 2, 2026
Enrollment to primary: 23 daysPosted 6.7 years ago
Interventions
TAK-123drug
TAK-123 infusion